Table 2.

Transition in best-corrected visual acuity and central retinal thickness of each group

	Group 1	Group 2	Group 3
BCVA (logMAR)
Baseline	0.82 ± 0.47	0.78 ± 0.55	0.82 ± 0.38
3 months	0.95 ± 0.36	0.66 ± 0.37	0.80 ± 0.44
6 months	1.01 ± 0.31	0.56 ± 0.37*	0.82 ± 0.40
12 months	1.05 ± 0.32	0.57 ± 0.35*	0.81 ± 0.42
CRT (μm)
Baseline	315 ± 93	358 ± 88	314 ± 102
3 months	268 ± 104	204 ± 72*	211 ± 51*
6 months	260 ± 93	202 ± 84*	223 ± 51*
12 months	263 ± 84	241 ± 74*	202 ± 46*

Notes: Group 1, PDT monotherapy; Group 2, STA + PDT; Group 3, IVR + PDT;

^*P < 0.05 versus baseline.

Abbreviations: CRT, central retinal thickness; BCVA, best corrected visual acuity; PDT, photodynamic therapy; STA, subtenon injection of triamcinolone acetonide; IVR, intravitreal injection of ranibizumab.